All In Biotech

Drug Trial Radar · NCT07741526

Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

A Phase 2a Multi-site, Randomized, Double-blind, Dose Escalated, Placebo Controlled Biomarker Study to Determine the Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI (Mild Cognitive Impairment) or Mild Dementia Due to Alzheimer's Disease (AD) Aged 50 to 85 Years

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

33

Actual

Start

Oct 14, 2025

Primary completion

Apr 30, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Arctic TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Blueskin AS
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD). In the study participants receive increasing dose of active treatment (250mg vs 500mg vs 750mg) or matched placebo in the form of tablets BID.

Conditions

  • Alzheimer´s Disease

Interventions

  • NPI-001Drug

    NPI-001 tablets administered orally BID at escalating doses of 250 mg, 500 mg, and 750 mg for period of 12 months

  • PlaceboDrug

    Placebo tablets administered orally BID at escalating doses of 250 mg, 500 mg, and 750 mg for period of 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment -Emergent Adverse EventsTime frame: Through study completion, approximately up to 14 months
  2. Safety labs results within normal rangeTime frame: Through study completion, approximately up to 14 months
  3. Assessment of ARIA H and ARIA E in the brain with MRI imagingTime frame: Through study completion, approximately up to 14 months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Sanos Clinic Gandrup

    Gandrup, Denmark

  • Sanos Clinic Herlev

    Herlev, Denmark

  • Sanos Clinic Vejle

    Vejle, Denmark

  • Landspitali University Hospital

    Reykjavik, Iceland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.